Small Cell Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Digitally generated lungs held by doctor | Image credit: Image credit: PRASANNAPIX - stock.adobe.com
Chemo Plus IO Offers Survival Benefit in ES-SCLC vs Chemo Alone in Real-World Study

April 29th 2025

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung cancer (ES-SCLC).

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

OS was the primary end point in the trial, and data from the planned interim analysis will be presented at an upcoming scientific meeting. | Image credit: Crystal light - stock.adobe.com
Tarlatamab Improves Overall Survival in Extensive-Stage SCLC

April 14th 2025

The new study suggests LTF should be considered as a potential biomarker of first-line treatment response in patients with ES-SCLC. | Image credit: appledesign - stock.adobe.com
Baseline LTF Linked With Treatment Response in SCLC

April 8th 2025

Doctor showing patient x-ray of lung cancer. | Image credit: Nattakorn – stock.adobe.com
3 DDR Phenotypes May Predict Chemotherapy Response in SCLC

March 25th 2025

Multidisciplinary Approaches to Paraneoplastic LEMS

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

More News

Image of healthy and diseased lungs
February 7th 2023

Randomized Prospective Trial Suggests AI Improves Lung Cancer Screening

Jared Kaltwasser
Artificial intelligence (AI) improved detection of actionable lung nodules without leading to higher rates of false positives, the study found.
NCCN Guideline Update Reflects Rise of Precision Options in NSCLC
February 5th 2023

NCCN Guideline Update Reflects Rise of Precision Options in NSCLC

Mary Caffrey
The latest updates in non–small cell lung cancer (NSCLC) cover recommendations for diagnostics, staging, when to use biomarker testing, sequencing of therapeutic options, and the addition of new treatments.
COTA Joins Multistakeholder Clinical Research Data Sharing Alliance
January 31st 2023

COTA Joins Multistakeholder Clinical Research Data Sharing Alliance

Rose McNulty
The real-world oncology data and analytics company COTA has joined the Clinical Research Data Sharing Alliance, a nonprofit consortium that aims to accelerate progress in cancer therapy development.
Targeted Therapies for NSCLC May Be Underused in Medicaid Programs, Study Suggests
January 29th 2023

Targeted Therapies for NSCLC May Be Underused in Medicaid Programs, Study Suggests

Rose McNulty
A new study estimates that prescription of standard-of-care non–small-cell lung cancer (NSCLC) therapies is lower than expected in Medicaid programs, with significant variation between states.
Timothy Murphy, MD, Rocky Mountain Cancer Centers
January 26th 2023

Dr Timothy Murphy Discusses How COVID-19 Has Affected Lung Cancer Screening

Julia Bonavitacola Laura Joszt, MA
Timothy Murphy, MD, FACP, practice president of Rocky Mountain Cancer Centers, spoke with The American Journal of Managed Care® about the effect of the COVID-19 pandemic on screening for lung cancer.
Image of lung cancer research
January 23rd 2023

PD-L1 Scoring in NSCLC Varies Significantly

Jared Kaltwasser
This new study has found different labs followed similar practices, but the way they scored patients varied significantly.
Timothy Murphy, MD, Rocky Mountain Cancer Centers
January 20th 2023

Dr Timothy Murphy Discusses Racial Disparities in Lung Cancer Screenings

Julia Bonavitacola Laura Joszt, MA
Timothy Murphy, MD, FACP, current practice president at Rocky Mountain Cancer Centers, spoke with The American Journal of Managed Care® about the current state of lung cancer screenings.
Colorful lung graphic
January 17th 2023

Potential Molecular Mechanisms That Increase COVID-19 Risk in Lung Cancer Highlighted

Jared Kaltwasser
This experimental research suggests the expression levels of certain genes might help explain why people with lung cancer often have more severe cases of COVID-19.
Image of genetic code
January 10th 2023

Investigators Find Potential Biomarker for Platinum-Based Chemotherapy Response in NSCLC

Jared Kaltwasser
Patients who had non–small cell lung cancer (NSCLC) with homologous recombination gene mutations had better outcomes, although no single gene in the pathway appeared to have a causal role.
Image of Clostridioides difficile bacteria
January 9th 2023

Concurrent Antibiotics, Steroids Raise CDI Risk in People With Lung Cancer Receiving EGFR-TKIs

Jared Kaltwasser
The new report found no evidence that second-generation tyrosine kinase inhibitors (TKIs) were more likely to lead to Clostridioides difficile infection (CDI) in patients with lung cancer.
Lab workers preparing samples
January 5th 2023

Tumor-Associated Autoantibodies Demonstrate Promise as Immunotherapy Biomarkers in NSCLC

Julia Bonavitacola
The development of 2 panels measuring levels of tumor-associated autoantibodies (TAAbs) has promise for predicting therapeutic response and adverse events for patients with advanced non–small cell lung cancer (NSCLC) after immune checkpoint inhibitor–based treatment.
Administering Antimicrobial Therapy Before CIT May Be Safer Option in NSCLC
January 5th 2023

Administering Antimicrobial Therapy Before CIT May Be Safer Option in NSCLC

Julia Bonavitacola
This study investigated the effects of antimicrobial therapy among patients with non–small cell lung cancer (NSCLC) who received immunotherapy with a checkpoint inhibitor or chemotherapy plus immunotherapy (CIT).
Hilary Tindle, MD, MPH, Associate Professor of Medicine, Vanderbilt University
December 27th 2022

Dr Hilary Tindle Discusses NMR and Precision Approaches in Cancer Care

Pearl Steinzor
Hilary Tindle, MD, MPH, associate professor of medicine, Vanderbilt University, spoke about the use of precision medicine approaches, such as the nicotine metabolite ratio (NMR), to improve outcomes for patients with lung cancer.
Dr Davey Daniel Talks Approval of Cemiplimab With Chemotherapy for First-line NSCLC
December 21st 2022

Dr Davey Daniel Talks Approval of Cemiplimab With Chemotherapy for First-line NSCLC

Mary Caffrey Hayden E. Klein
Cemiplimab with chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.
Hilary Tindle, MD, MPH, Associate Professor of Medicine, Vanderbilt University
December 20th 2022

Dr Hilary Tindle: Tobacco Nation's High Rates of Lung Cancer

Pearl Steinzor
Hilary Tindle, MD, MPH, associate professor of medicine, Vanderbilt University, spoke on increased rates of smoking and lung cancer within a particular region of the United States called "Tobacco Nation."
graphic indicating genetic code
December 9th 2022

Switch to NGS Would Lead to More Targeted NSCLC Care, but May Not Lower Costs

Jared Kaltwasser
The study, based on care in Japan, found patients would be more quickly referred for targeted therapy.
picture of cannabis
December 7th 2022

Cannabis Used With ICIs Appears to Have No Impact on NSCLC Outcomes

Jared Kaltwasser
Differences in overall survival between cannabis users and those who did not use the plant were small and could be explained by differences in the make-ups of the 2 cohorts of patients with non-small cell lung cancer, researchers said.
Image of lung cancer
November 29th 2022

Afatinib Outperforms First-Generation EGFR-TKIs in NSCLC With Uncommon EGFR Mutations

Jared Kaltwasser
The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations.
Lungs and stethoscope
November 22nd 2022

Early Lung Cancer Screening Program Dramatically Increases Survival Rates

Pearl Steinzor
A recent study stresses the importance of routine CT screening for improving lung cancer survival outcomes.
Lungs
November 16th 2022

Despite Improvements in Lung Cancer Screening, Increased Efforts Still Needed to Address Disparities

Justina Petrullo
The State of Lung Cancer 2022 report issued by the American Lung Association illustrates aspects of diagnosis and care that require additional attention to address disparities and increase nationwide screening and treatment engagement while reducing risk factor exposure.
image of research
November 13th 2022

Doubling Women’s Lung Cancer Research Funding Would Generate Major Returns, Study Says

Jared Kaltwasser
Lung cancer is the number one cause of cancer-related deaths among women in the United States, yet relatively little research funding is spent on the issue, the authors of a new study say.
FDA approved cemiplimab plus chemotherapy for NSCLC
November 9th 2022

FDA Approves Cemiplimab Plus Chemotherapy as First-line NSCLC Treatment

Allison Inserro
The FDA approved cemiplimab (Libtayo) in combination with platinum-based chemotherapy for the first-line treatment of advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.
In Advanced NSCLC, Forgoing Treatment Leads to Increased Health Care Utilization
November 6th 2022

In Advanced NSCLC, Forgoing Treatment Leads to Increased Health Care Utilization

Jared Kaltwasser
A new report underscores how treatment decisions for non-small cell lung cancer (NSCLC) affect patients’ health care utilization and costs.
Image of lung cancer
October 26th 2022

Meta-Analysis Supports Immune Checkpoint Inhibitors in Frontline NSCLC Treatment

Rose McNulty
Immune checkpoint inhibitors, either alone or in combination with chemotherapy, were associated with better outcomes in non–oncogene-addicted non–small cell lung cancer (NSCLC).
Emphasizing Biomarker-Driven Treatment and Individualized Care Strategies for Patients With NSCLC
October 21st 2022

Emphasizing Biomarker-Driven Treatment and Individualized Care Strategies for Patients With NSCLC

Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).
JAVELIN Lung 100 Trial Evaluating Progression-Free and Overall Survival for Patients With NSCLC
October 14th 2022

JAVELIN Lung 100 Trial Evaluating Progression-Free and Overall Survival for Patients With NSCLC

Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.
Immunotherapy graphic
October 9th 2022

Immunotherapy in SCC Still Marred by Challenges, Despite Efficacy in Some Patients

Jared Kaltwasser
Among the challenges are a lack of reliable biomarkers and resistance in some patients who have squamous cell carcinoma (SCC).
HUDSON Trial Overview and Key Takeaways
October 7th 2022

HUDSON Trial Overview and Key Takeaways

The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.
Ticiana Leal, MD, Emory University School of Medicine
October 7th 2022

Dr Ticiana Leal: A Lot of Work Is Needed Regarding Early Detection in Lung Cancer

Laura Joszt, MA Skylar Jeremias
Lung cancer screening rates remain low nationwide, and there is a need to better educate patients and clinicians about the importance of screening, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Person walking on a country road
October 6th 2022

NSCLC Differs Between Rural, Urban Patients in Key Ways

Jared Kaltwasser
Molecular differences may help explain geographic gaps in outcomes.
<12345678
...
10>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo